AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22688548 — intervention group
Group type: EXPERIMENTAL
Intervention: LGI-LC diet
Number of subjects: 26
Study 22688548 — intervention group
Group type: COMPARATOR
Intervention: HGI-HC diet
Number of subjects: 26
Study 20841411 — intervention group
Group type: EXPERIMENTAL
Intervention: AnaConDa® (ACD)
Number of subjects: 30
Study 20841411 — intervention group
Group type: COMPARATOR
Intervention: Conventional vaporizer
Number of subjects: 30
Study 18242137 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial Maze
Number of subjects: 160
Study 18242137 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Maze
Number of subjects: 160
Study 18242137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Vein Isolation Maze
Number of subjects: 160
Study 18242137 — intervention group
Group type: COMPARATOR
Intervention: No Maze (Control)
Number of subjects: 160
Study 15915393 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg IV followed by titration)
Number of subjects: 40
Study 15915393 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (1 mg IV every 2 minutes)
Number of subjects: 40
Study 15915393 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 15915393 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 12792259 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus coping
Number of subjects: 109
Study 12792259 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping instruction
Number of subjects: 109
Study 12792259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study 10994627 — intervention group
Group type: EXPERIMENTAL
Intervention: Child stage B/C cirrhosis patients
Number of subjects: 108
Study 10994627 — intervention group
Group type: EXPERIMENTAL
Intervention: Child stage B/C cirrhosis patients with creatinine > or = 1.4 mg/dl
Number of subjects: 108
Study 10994627 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108
Study 8800032 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 28
Study 8800032 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 28
Study 1843597 — intervention group
Group type: EXPERIMENTAL
Intervention: Toloxatone (400 mg daily for 6 weeks)
Number of subjects: 101
Study 1843597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 3922214 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Cytoxan, Hexamethylmelamine, and Fluorouracil (CHF)
Number of subjects: 40
Study 3922214 — intervention group
Group type: COMPARATOR
Intervention: L-phenylalanine mustard (L-pam)
Number of subjects: 40
Study 3922214 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF as a second-line therapy
Number of subjects: 40
Study 3922214 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF in patients with complete resection of less than 2 cm residual disease
Number of subjects: 40
Study 3922214 — intervention group
Group type: COMPARATOR
Intervention: L-pam in patients with complete resection of less than 2 cm residual disease
Number of subjects: 40
Study 3922214 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF in second-look operations
Number of subjects: 40
Study 29224127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with etanercept and methotrexate
Number of subjects: 141
Study 29224127 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of etanercept or methotrexate (control)
Number of subjects: 141
Study 26809952 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow withdrawal schedule (160 days)
Number of subjects: 350
Study 26809952 — intervention group
Group type: COMPARATOR
Intervention: Rapid withdrawal schedule (60 days)
Number of subjects: 350
Study 24395436 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MP starting dose <75 mg/m(2)/day in ALL2000 cohort
Number of subjects: 1275
Study 24395436 — intervention group
Group type: COMPARATOR
Intervention: 6MP starting dose 75 mg/m(2)/day in ALL92 cohort
Number of subjects: 1275
Study 24395436 — intervention group
Group type: EXPERIMENTAL
Intervention: TPMT(LA) patients in ALL2000 cohort
Number of subjects: 1275
Study 24395436 — intervention group
Group type: COMPARATOR
Intervention: TPMT(LA) patients in ALL92 cohort
Number of subjects: 1275
Study 22452288 — intervention group
Group type: EXPERIMENTAL
Intervention: RV mid-septum
Number of subjects: 215
Study 22452288 — intervention group
Group type: COMPARATOR
Intervention: RV apex
Number of subjects: 215
Study 21269349 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (TC) cream and intense pulsed light (IPL)
Number of subjects: 56
Study 21269349 — intervention group
Group type: COMPARATOR
Intervention: Inactive control cream and intense pulsed light (IPL)
Number of subjects: 56
Study 19292281 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total hip arthroplasty
Number of subjects: 0
Study 19292281 — intervention group
Group type: COMPARATOR
Intervention: Standard total hip arthroplasty
Number of subjects: 0
Study 16878032 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning predictor (f/Vt) used in decision to wean (n = 153)
Number of subjects: 304
Study 16878032 — intervention group
Group type: COMPARATOR
Intervention: Weaning predictor (f/Vt) not used in decision to wean (n = 151)
Number of subjects: 304
Study 16878032 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning predictor (f/Vt) used in decision to wean
Number of subjects: 304
Study 16878032 — intervention group
Group type: COMPARATOR
Intervention: Weaning predictor (f/Vt) not used in decision to wean
Number of subjects: 304
Study 12631046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 20
Study 12631046 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 20
Study 11070907 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 0
Study 9013270 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg) + Prazosin (1 mg)
Number of subjects: 17
Study 9013270 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5 mg)
Number of subjects: 17
Study 1393155 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactiling (speechreading with tactile supplement)
Number of subjects: 8
Study 1393155 — intervention group
Group type: COMPARATOR
Intervention: Speechreading alone
Number of subjects: 8
Study 3156109 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 2508
Number of subjects: 0
Study 3156109 — intervention group
Group type: EXPERIMENTAL
Intervention: RO‐03‐8799
Number of subjects: 0
Study 3156109 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 2508 and RO‐03‐8799
Number of subjects: 0
Study 3156109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitizers (general)
Number of subjects: 0
Study 31450084 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted bed bath simulation
Number of subjects: 56
Study 31450084 — intervention group
Group type: COMPARATOR
Intervention: Control group (tutor instructions only)
Number of subjects: 56
Study 29723595 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Disease Management Program (HF-DMP)
Number of subjects: 0
Study 29723595 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 27173230 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogen sulfate (CHS)
Number of subjects: 119
Study 27173230 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel benzene sulfonate (CB)
Number of subjects: 119
Study 23846352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion-to-ventricle distance in persistent black holes (PBHs)
Number of subjects: 289
Study 23846352 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised linear mixed multivariate model adjusted for BHs clustered within a patient
Number of subjects: 289
Study 23846352 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall persistence of new black holes
Number of subjects: 289
Study 22312032 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention based on events with short counselling and self-help materials
Number of subjects: 514
Study 22312032 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 514
Study 20107306 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 0
Study 20107306 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 18022341 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling and education from migrant health educators as adjuncts to GP care
Number of subjects: 104
Study 18022341 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment from GPs
Number of subjects: 104
Study 16208051 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) therapy at a dose of 13.1 mg/dL
Number of subjects: 28
Study 16208051 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) therapy
Number of subjects: 28
Study 16208051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 12297966 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated group (n = 32) with maxillary expansion
Number of subjects: 89
Study 12297966 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated group (n = 32)
Number of subjects: 89
Study 12297966 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25) with excellent occlusion
Number of subjects: 89
Study 9925135 — intervention group
Group type: EXPERIMENTAL
Intervention: 34 g conventional soy
Number of subjects: 0
Study 9925135 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g conventional soy
Number of subjects: 0
Study 9925135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-oligosaccharide soy
Number of subjects: 0
Study 9925135 — intervention group
Group type: COMPARATOR
Intervention: Control rice meal
Number of subjects: 0
Study 8530764 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable aggressive group
Number of subjects: 177
Study 8530764 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable aggressive group
Number of subjects: 177
Study 8530764 — intervention group
Group type: COMPARATOR
Intervention: Nonaggressive group
Number of subjects: 177
Study 1978963 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 1298
Study 1978963 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 1298
Study 6794365 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid administered under fasting conditions (250 mg soft-gelatin capsules)
Number of subjects: 8
Study 6794365 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid administered under nonfasting conditions (250 mg soft-gelatin capsules)
Number of subjects: 8
Study 6794365 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid administered under nonfasting conditions (250 mg soft-gelatin capsules, excluding one subject who exercised)
Number of subjects: 8
Study 6794365 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid administered under fasting and nonfasting conditions
Number of subjects: 8
Study 6794365 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid administered with food
Number of subjects: 8
Study 31505967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (10 min a day for 2 weeks)
Number of subjects: 994
Study 31505967 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual muscle relaxation (10 min a day for 2 weeks)
Number of subjects: 994
Study 31505967 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 994
Study 27306945 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium infantis M‐63, breve M‐16V, and longum BB536 for 6 weeks
Number of subjects: 73
Study 27306945 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 73
Study 26002612 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based childhood obesity intervention delivered by patient navigators, consisting of a 16-session curriculum focused on parenting styles, nutrition, and physical activity.
Number of subjects: 0
Study 26002612 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention groups (control group) until the start of the intervention.
Number of subjects: 0
Study 23566176 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW route (lower proximity to motorised traffic)
Number of subjects: 35
Study 23566176 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW route
Number of subjects: 35
Study 21501216 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10, 20 or 40 mg day(‐1)) with 300 ml day(‐1) of 100% grapefruit juice for 90 days
Number of subjects: 130
Study 21501216 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (50% reduced dose) with 300 ml day(‐1) of 100% grapefruit juice for 90 days
Number of subjects: 130
Study 19135860 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication committees (ACs) reported in RCTs
Number of subjects: 314
Study 19135860 — intervention group
Group type: EXPERIMENTAL
Intervention: ACs in trials with low risk of misclassification
Number of subjects: 314
Study 19135860 — intervention group
Group type: EXPERIMENTAL
Intervention: ACs in trials with medium risk of misclassification
Number of subjects: 314
Study 19135860 — intervention group
Group type: EXPERIMENTAL
Intervention: ACs in trials with high risk of misclassification
Number of subjects: 314
Study 19135860 — intervention group
Group type: EXPERIMENTAL
Intervention: Events identified by site investigators
Number of subjects: 314
Study 19135860 — intervention group
Group type: EXPERIMENTAL
Intervention: Data provided to the AC
Number of subjects: 314
Study 17228552 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening for cognitive impairment
Number of subjects: 0
Study 17228552 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of healthcare staff in prevention, screening, and detection of delirium
Number of subjects: 0
Study 14586484 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (specifics not provided), often in combination with mood stabilizers
Number of subjects: 20
Study 14586484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 20
Study 14586484 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 20
Study 14586484 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (open-label trial)
Number of subjects: 20
Study 14586484 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (double-blind placebo-controlled trials)
Number of subjects: 20
Study 14586484 — intervention group
Group type: COMPARATOR
Intervention: Double-blind crossover trial (specifics not provided)
Number of subjects: 20
Study 14586484 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label group (citalopram)
Number of subjects: 20
Study 10669337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea/didanosine combination therapy
Number of subjects: 80
Study 10669337 — intervention group
Group type: COMPARATOR
Intervention: Didanosine monotherapy
Number of subjects: 80
Study 9065377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 10 mg
Number of subjects: 54
Study 9065377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium 50 mg
Number of subjects: 54
Study 9065377 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg loading/275 mg repeat doses
Number of subjects: 54
Study 9065377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8380540 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir, 400 mg twice daily
Number of subjects: 56
Study 8380540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 3549595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclospasmol 400 mg taken 4 times daily for 12 months
Number of subjects: 26
Study 3549595 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules taken 4 times daily for 12 months
Number of subjects: 26
Study 30371182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) lowering (<120 mm Hg)
Number of subjects: 0
Study 30371182 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure (SBP) goals (<140 mm Hg)
Number of subjects: 0
Study 26949762 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy (SPT) on time for group S1
Number of subjects: 400
Study 26949762 — intervention group
Group type: COMPARATOR
Intervention: Erratic compliance (S2)
Number of subjects: 400
Study 26949762 — intervention group
Group type: COMPARATOR
Intervention: Failing compliance (S3)
Number of subjects: 400
Study 24398757 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 12
Study 24398757 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/remifentanil
Number of subjects: 12
Study 24707373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of Estriol as a vaginal cream
Number of subjects: 414
Study 24707373 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 414
Study 20008886 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol
Number of subjects: 220
Study 20008886 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist protocol
Number of subjects: 220
Study 17533394 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal biopsy
Number of subjects: 200
Study 17533394 — intervention group
Group type: COMPARATOR
Intervention: Transrectal biopsy
Number of subjects: 200
Study 17533394 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal biopsy in gray zone PSA (4.1 to 10.0 ng/ml)
Number of subjects: 200
Study 15534360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy combined with two cycles of concomitant cisplatin (20 mg/m2 on 5 days of weeks 1 and 5)
Number of subjects: 224
Study 15534360 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy alone (median dose, 74.4 Gy; 1.2 Gy twice daily)
Number of subjects: 224
Study 15534360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy combined with two cycles of concomitant cisplatin
Number of subjects: 224
Study 15534360 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy alone
Number of subjects: 224
Study 11552168 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexi‐Flow titanium‐reinforced composite resin cement
Number of subjects: 120
Study 11552168 — intervention group
Group type: COMPARATOR
Intervention: Zinc phosphate cement
Number of subjects: 120
Study 11552168 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel‐sided ParaPost dowels
Number of subjects: 120
Study 9467542 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 25 mg daily for 8 weeks
Number of subjects: 24
Study 10147420 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser surgery (maximal power, 40-60 W)
Number of subjects: 60
Study 10147420 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (scalpel and electrosurgery)
Number of subjects: 60
Study 2961787 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 1600 mg/day for 28 days
Number of subjects: 10
Study 2961787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28358525 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment individual placement and support (IPS)
Number of subjects: 541
Study 28358525 — intervention group
Group type: COMPARATOR
Intervention: Stepwise vocational transitional work program (TWP)
Number of subjects: 541
Study 28859690 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphefekt in a cetomacrogol-based cream
Number of subjects: 100
Study 28859690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25673113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium supplementation (3 g d(-1), equals 7.6 g d(-1) of salt)
Number of subjects: 37
Study 25673113 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (3 g d(-1))
Number of subjects: 37
Study 25673113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 25673113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium and potassium supplementation
Number of subjects: 37
Study 23830559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 0.01% (0.1 mg/mL) for 60 seconds
Number of subjects: 60
Study 23830559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 0.01% (0.1 mg/mL) for 30 seconds
Number of subjects: 60
Study 23830559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 0.01% (0.1 mg/mL) for 15 seconds
Number of subjects: 60
Study 23830559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 21395644 — intervention group
Group type: COMPARATOR
Intervention: Neratinib 240 mg alone
Number of subjects: 24
Study 21395644 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg with ketoconazole 400 mg
Number of subjects: 24
Study 18438103 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa and Hib vaccine (mixed prior to administration)
Number of subjects: 119
Study 18438103 — intervention group
Group type: COMPARATOR
Intervention: DTPa and Hib vaccine (separate injections)
Number of subjects: 119
Study 16945613 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1 g/day as citrate)
Number of subjects: 1471
Study 12877601 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced ultrasound
Number of subjects: 30
Study 12877601 — intervention group
Group type: COMPARATOR
Intervention: CTA or MRA
Number of subjects: 30
Study 12162240 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized instruction supported by written information
Number of subjects: 45
Study 12162240 — intervention group
Group type: COMPARATOR
Intervention: Written information alone
Number of subjects: 45
Study 12162240 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help behaviors initiated by participants
Number of subjects: 45
Study 9307820 — intervention group
Group type: EXPERIMENTAL
Intervention: Common ground stimulation mode
Number of subjects: 32
Study 9307820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudo-monopolar mode
Number of subjects: 32
Study 9307820 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro measurements with functioning cochlear implant
Number of subjects: 32